{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:18:44Z","timestamp":1787894324149,"version":"build-2784847793"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Autoimmune hepatitis (AIH) is a complex immune-mediated liver disease of unknown origin that can rapidly progress to liver cirrhosis and end-stage liver failure. Standard treatment regimens typically involve immunosuppressive therapies, with most patients requiring lifelong maintenance. Recently, cell therapy has emerged as a potential therapeutic option for AIH. In this study, we report the case of a 2-year-old boy with type 2 autoimmune hepatitis and postcardiac arrest cerebral palsy who experienced clinical and biochemical improvement following umbilical cord-derived mesenchymal stromal cell (UC-MSC) infusion. Six months after the cell infusion, liver enzyme levels markedly reduced and remained stable throughout the 1-year follow-up period. At 1 year post-infusion, the patient demonstrated significant improvements in motor function, language skill, along with reduced hypertonia. At the most recent follow-up, his liver enzyme levels were within the normal range, and he had made substantial progress toward achieving developmental milestones. These clinical and biochemical changes suggest that UC-MSC therapy has potential as an adjunctive therapeutic approach. However, because this is a single, uncontrolled observation with several concurrent confounders, the clinical efficacy of UC-MSC therapy cannot be established from this case alone. Larger-scale studies with appropriate control groups, longer follow-up periods, and more detailed mechanistic assessments are required to determine whether UC-MSC therapy provides a true therapeutic benefit. No infusion-related adverse events were observed during follow-up.<\/jats:p>","DOI":"10.3389\/fmed.2026.1844700","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:31:49Z","timestamp":1787891509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Improvement in liver function and gross motor function after umbilical cord-derived mesenchymal stromal cell transplantation in a child with autoimmune hepatitis and concurrent cerebral palsy: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Liem","family":"Thanh Nguyen","sequence":"first","affiliation":[{"name":"Vinmec Research Institute of Stem Cell and Gene Technology, VinUniversity","place":["Hanoi, Vietnam"]},{"name":"Regenerative Medicine and Cell Therapy Center, Vinmec Healthcare System","place":["Hanoi, Vietnam"]},{"name":"Vinmec Smart City International Hospital","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong Thu","family":"Le","sequence":"additional","affiliation":[{"name":"Vinmec Smart City International Hospital","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doan","family":"Van Ngo","sequence":"additional","affiliation":[{"name":"Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Kieu Trang","family":"Phan","sequence":"additional","affiliation":[{"name":"Vinmec Research Institute of Stem Cell and Gene Technology, VinUniversity","place":["Hanoi, Vietnam"]},{"name":"Innovation Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9437043","DOI":"10.1155\/2019\/9437043","article-title":"Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies","volume":"2019","author":"Sucher","year":"2019","journal-title":"J Immunol Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5009\/gnl19261","article-title":"Autoimmune Hepatitis: 2019 Update","volume":"14","author":"Tanaka","year":"2020","journal-title":"Gut Liver"},{"key":"B3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2025.03.017","article-title":"EASL Clinical Practice Guidelines on the management of autoimmune hepatitis","volume":"83","year":"2025","journal-title":"J Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7199\/ped.oncall.2014.53","article-title":"Autoimmune Liver Disease","volume":"11","author":"Liberal R","year":"2014","journal-title":"Pediatr Oncall"},{"key":"B5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/flgastro-2021-101928","article-title":"Provision and standards of care for treatment and follow-up of patients with auto-immune hepatitis (AIH)","volume":"13","author":"Chapman","year":"2022","journal-title":"FrontGastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/liv.14062","article-title":"Autoimmune hepatitis: current and future therapeutic options","volume":"39","author":"Doycheva","year":"2019","journal-title":"Liver Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/bmj.p330","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"380","author":"Muratori","year":"2023","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: Autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"989473","DOI":"10.1155\/2015\/989473","article-title":"Mesenchymal stromal cells affect disease outcomes via macrophage polarization","volume":"2015","author":"Zheng","year":"2015","journal-title":"Stem Cells Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/ijms27020619","article-title":"Mesenchymal Stromal\/Stem Cell-Based Therapies for Liver Regeneration: Current Status and Future Directions","volume":"27","author":"Choi","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2040622321993442","DOI":"10.1177\/2040622321993442","article-title":"Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges","volume":"12","author":"He","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jcyt.2020.09.004","article-title":"Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem\/stromal cells from perinatal and adult tissue sources","volume":"23","author":"Hoang","year":"2021","journal-title":"Cytotherapy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/sctm.20-0102","article-title":"Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder","volume":"10","author":"Nguyen Thanh","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5966\/sctm.2012-0034","article-title":"Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients","volume":"1","author":"Shi","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s13770-019-00178-y","article-title":"Stem Cell-Based Therapies for Liver Diseases: An Overview and Update","volume":"16","author":"Wang","year":"2019","journal-title":"Tissue Eng Regen Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13578-020-00480-6","article-title":"Mesenchymal stem cell therapy for liver disease: full of chances and challenges","volume":"10","author":"Yang","year":"2020","journal-title":"Cell Biosci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1096402","DOI":"10.3389\/fimmu.2022.1096402","article-title":"Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"108004","DOI":"10.1016\/j.pharmthera.2021.108004","article-title":"Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells","volume":"232","author":"Zhang","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6546780","DOI":"10.1155\/2021\/6546780","article-title":"Applications of Mesenchymal Stem Cells in Liver Fibrosis: Novel Strategies, Mechanisms, and Clinical Practice","volume":"2021","author":"Zhu","year":"2021","journal-title":"Stem Cells Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"13292","DOI":"10.3390\/ijms222413292","article-title":"Regenerative Potential of Mesenchymal Stem Cells' (MSCs) Secretome for Liver Fibrosis Therapies","volume":"22","author":"Nazarie Ignat","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13287-016-0394-0","article-title":"Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies","volume":"7","author":"Hofer","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/biom14050538","article-title":"MSC-Based Cell Therapy in Neurological Diseases: A Concise Review of the Literature in Pre-Clinical and Clinical Research","volume":"14","author":"Zhang","year":"2024","journal-title":"Biomolecules"},{"key":"B26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1742-2094-10-106","article-title":"Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury","volume":"10","author":"Zhang","year":"2013","journal-title":"J Neuroinflammation"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1844700\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:32:01Z","timestamp":1787891521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1844700\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1844700"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1844700","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1844700"}}